Symposium | The next wave of immune-based therapies: What you need to know in relapsed/refractory multiple myeloma

During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled ‘Sequencing immune-based therapies in B-cell malignancies’. Here the Multiple Myeloma Hub is pleased to share the session: Next wave of immune-based therapies: What you need to know, which focused on relapsed/refractory (R/R) multiple myeloma (MM) and was presented by Krina Patel, MD Anderson Cancer Center, Houston, US. This activity was supported through an educational grant from Bristol Myers Squibb. Hosted on Acast. See acast.com/privacy for more information.